RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.

doi:10.1158/2326-6066.CIR-25-0744

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.

Cancer immunology research - 8 Jan 2026

Anastacio Da Costa Carvalho Larissa, Tovbis Shifrin Nataliya, Phadke Manali S, Emmons Michael F, Pechuan-Jorge Ximo, Mbuga Felix, Ospina Oscar E, Chow Christopher, Seu Lillian, Rose Olivia L, Hegde Aparna, Khushalani Nikhil I, Quintana Elsa, Smalley Keiran S M

Abstract excerpt

Targeted therapies for NRAS-mutant melanoma remain an unmet clinical need. In this study, we demonstrate that RMC-7977, a preclinical RAS(ON) multiselective inhibitor representative of the investigational agent daraxonrasib (RMC-6236), was able to elicit potent antitumor immune responses across multiple NRAS-mutant melanoma models. Treatment with RMC-7977 led to rapid tumor regressions driven by inhibition of...

Read the complete abstract on PubMed

Topics

Animals
Melanoma
Mice
Humans
GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

Membrane Proteins

Female

Cell Line, Tumor

Disease Models, Animal

Xenograft Model Antitumor Assays

CD8-Positive T-Lymphocytes

Monomeric GTP-Binding Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41186497
DOI: 10.1158/2326-6066.CIR-25-0744
PMCID: PMC12666865

Genes

NRAS
CD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.PMID 41186497Read ↗

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma.Semantic proximity Read ↗

Macrophage Antigen Presentation Is Unleashed by Pan-RAS Inhibition to Promote Antitumor ImmunitySemantic proximity Read ↗

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in <i>NRAS</i> -Mutated MelanomaSemantic proximity Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

A mutation-resolved therapeutic atlas of NRAS-mutant melanoma reveals genotype-selective response to RAS(ON) inhibition and adaptive STAT3 survivalSemantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Semantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.Semantic proximity Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.